Formosa Pharmaceuticals, Inc. (TPE:6838)
Taiwan · Delayed Price · Currency is TWD 22.65
+0.20 (0.89%)
Aug 19, 2026, 1:30 PM CST
Formosa Pharmaceuticals Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 52.59 | 9.5 | 143.36 | 31.17 | 1.32 | 28.53 | |
Revenue Growth | 237.39% | -93.38% | 359.89% | 2270.49% | -95.39% | - |
Cost of Revenue | 22.43 | 11.09 | 24.37 | 3.83 | 0.98 | 0.27 |
Gross Profit | 30.16 | -1.6 | 118.99 | 27.35 | 0.33 | 28.26 |
Selling, General & Admin | 42.7 | 47.63 | 60.8 | 40.2 | 25.53 | 20.65 |
Research & Development | 157.79 | 121.38 | 226 | 270.18 | 356.47 | 387.62 |
Operating Expenses | 200.49 | 169.01 | 294.62 | 310.38 | 382 | 408.27 |
Operating Income | -170.33 | -170.61 | -175.63 | -283.04 | -381.67 | -380.01 |
Interest Expense | -0.51 | -0.49 | -0.57 | -4.31 | -0.99 | -2.21 |
Interest & Investment Income | 23.57 | 25.29 | 21.18 | 12.42 | 0.47 | 0.06 |
Currency Exchange Gain (Loss) | 13.96 | 13.96 | -18.62 | 9.29 | -25.15 | 20.97 |
Other Non Operating Income (Expenses) | -54.39 | 47.85 | 1.03 | 0.09 | 0.75 | 0.01 |
EBT Excluding Unusual Items | -187.71 | -84 | -172.61 | -265.54 | -406.59 | -361.18 |
Gain (Loss) on Sale of Assets | - | - | - | - | - | -0.2 |
Other Unusual Items | - | - | -6.96 | -34.53 | - | -37.04 |
Pretax Income | -187.71 | -84 | -179.57 | -300.07 | -406.59 | -398.42 |
Income Tax Expense | 2.26 | -0.43 | 21.36 | 21.86 | -0.42 | 2.4 |
Earnings From Continuing Operations | -189.97 | -83.57 | -200.93 | -321.93 | -406.17 | -400.82 |
Minority Interest in Earnings | -0.09 | 0.01 | -0.08 | -0.03 | -0.1 | -0.06 |
Net Income | -190.05 | -83.57 | -201.01 | -321.96 | -406.27 | -400.88 |
Net Income to Common | -190.05 | -83.57 | -201.01 | -321.96 | -406.27 | -400.88 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 153 | 151 | 141 | 124 | 105 | 92 |
Shares Outstanding (Diluted) | 153 | 151 | 141 | 124 | 105 | 92 |
Shares Change | 3.49% | 7.22% | 13.48% | 18.00% | 13.70% | 31.19% |
EPS (Basic) | -1.25 | -0.55 | -1.43 | -2.59 | -3.86 | -4.33 |
EPS (Diluted) | -1.25 | -0.55 | -1.43 | -2.59 | -3.86 | -4.33 |
EPS Growth | - | - | - | - | - | - |
Free Cash Flow | -294.68 | -105.65 | -135.95 | -198.21 | -346.15 | -331.35 |
Free Cash Flow Per Share | -1.93 | -0.70 | -0.96 | -1.60 | -3.29 | -3.58 |
Gross Margin | 57.35% | -16.83% | 83.00% | 87.73% | 25.32% | 99.06% |
Operating Margin | -323.92% | -1796.85% | -122.51% | -907.98% | -29024.26% | -1332.01% |
Profit Margin | -361.42% | -880.10% | -140.22% | -1032.84% | -30895.21% | -1405.18% |
Free Cash Flow Margin | -560.39% | -1112.70% | -94.83% | -635.85% | -26323.19% | -1161.46% |
EBITDA | -125.08 | -128.45 | -139.99 | -247.53 | -345.56 | -345.41 |
EBITDA Margin | -237.86% | - | -97.65% | - | - | - |
D&A For EBITDA | 45.25 | 42.17 | 35.64 | 35.51 | 36.11 | 34.6 |
EBIT | -170.33 | -170.61 | -175.63 | -283.04 | -381.67 | -380.01 |
EBIT Margin | - | - | -122.51% | - | - | - |